Aligos Therapeutics (ALGS) Non-Current Deffered Revenue (2020 - 2022)

Aligos Therapeutics has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $1.6 million in Q3 2022.

• For the quarter ending Q3 2022, Non-Current Deffered Revenue rose 13.49% year-over-year to $1.6 million; the trailing twelve-month figure through Sep 2022 stood at $1.6 million (up 13.49% YoY), and the FY2020 full-year result was $4.1 million, changed N/A from the prior year.
• Non-Current Deffered Revenue for Q3 2022 stood at $1.6 million, down from $3.3 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $5.0 million in Q1 2022, with the low at $1.4 million in Q3 2021.
• Historically, Non-Current Deffered Revenue has averaged $3.1 million across 3 years, with a median of $3.3 million in 2022.
• The largest YoY upside for Non-Current Deffered Revenue was 42.83% in 2022 against a maximum downside of 13.49% in 2022.
• Aligos Therapeutics' Non-Current Deffered Revenue stood at $4.1 million in 2020, then sank by 66.63% to $1.4 million in 2021, then climbed by 13.49% to $1.6 million in 2022.
• The last three Non-Current Deffered Revenue figures came in at $1.6 million (Q3 2022), $3.3 million (Q2 2022), and $5.0 million (Q1 2022), per Business Quant data.